PDK1 and acute myeloid leukemia: Efficacy of PDK1 inhibitors was also evaluated in a primary patient-derived xenograft scaffold mouse model, for which we took AML #22 that we previously extensively analyzed in this model39, which was shown to be sensitive to DAP in vitro, and was characterized as a relatively glycolytic AML based on Seahorse data (Supplementary Fig. 3q).